UNLABELLED: BACKGROUND/PATIENTS AND METHODS: 16 adult patients with untreated measurable locally advanced or metastatic inoperable soft tissue sarcoma were treated with oral perifosine, a synthetic alkylphospholipid, believed to inhibit MAP kinase (MAP-K), protein kinase C (PKC), Akt and other regulatory proteins. Perifosine was administered orally in cycles for 21 days out of 28. Loading doses were given day 1 each cycle (900 mg cycle 1, 300 mg cycle 2+) and 150 mg daily was given days 2-21 of each cycle. Cycles were repeated until disease progression, unacceptable toxicity or patient refusal. RESULTS: Seventeen patients were enrolled; 16 and 15 were evaluable for toxicity and response, respectively. A total of 30 cycles of perifosine were administered. Most toxic effects were grade 1 or 2 and commonly included nausea, vomiting, diarrhea, and fatigue (> or =40%). Hematologic toxicity was generally mild. There were no significant biochemical abnormalities due to the drug reported. There were 4 serious adverse events (SAE)-none of which was related to perifosine. No objective responses were seen; 4 patients had stable disease for 1.3 to 8.2 months and the remainder of the patients had progressive disease. CONCLUSIONS: Perifosine when given according to this dosing schedule does not show evidence of activity in a mixed population of adult soft tissue sarcoma patients.
UNLABELLED: BACKGROUND/PATIENTS AND METHODS: 16 adult patients with untreated measurable locally advanced or metastatic inoperable soft tissue sarcoma were treated with oral perifosine, a synthetic alkylphospholipid, believed to inhibit MAP kinase (MAP-K), protein kinase C (PKC), Akt and other regulatory proteins. Perifosine was administered orally in cycles for 21 days out of 28. Loading doses were given day 1 each cycle (900 mg cycle 1, 300 mg cycle 2+) and 150 mg daily was given days 2-21 of each cycle. Cycles were repeated until disease progression, unacceptable toxicity or patient refusal. RESULTS: Seventeen patients were enrolled; 16 and 15 were evaluable for toxicity and response, respectively. A total of 30 cycles of perifosine were administered. Most toxic effects were grade 1 or 2 and commonly included nausea, vomiting, diarrhea, and fatigue (> or =40%). Hematologic toxicity was generally mild. There were no significant biochemical abnormalities due to the drug reported. There were 4 serious adverse events (SAE)-none of which was related to perifosine. No objective responses were seen; 4 patients had stable disease for 1.3 to 8.2 months and the remainder of the patients had progressive disease. CONCLUSIONS:Perifosine when given according to this dosing schedule does not show evidence of activity in a mixed population of adult soft tissue sarcomapatients.
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: Vyomesh Patel; Tyler Lahusen; Terence Sy; Edward A Sausville; J Sivio Gutkind; Adrian M Senderowicz Journal: Cancer Res Date: 2002-03-01 Impact factor: 12.701
Authors: M Crul; H Rosing; G J de Klerk; R Dubbelman; M Traiser; S Reichert; N G Knebel; J H M Schellens; J H Beijnen; W W ten Bokkel Huinink Journal: Eur J Cancer Date: 2002-08 Impact factor: 9.162
Authors: George D Demetri; Margaret von Mehren; Charles D Blanke; Annick D Van den Abbeele; Burton Eisenberg; Peter J Roberts; Michael C Heinrich; David A Tuveson; Samuel Singer; Milos Janicek; Jonathan A Fletcher; Stuart G Silverman; Sandra L Silberman; Renaud Capdeville; Beate Kiese; Bin Peng; Sasa Dimitrijevic; Brian J Druker; Christopher Corless; Christopher D M Fletcher; Heikki Joensuu Journal: N Engl J Med Date: 2002-08-15 Impact factor: 91.245
Authors: Sudhir B Kondapaka; Sheo S Singh; Girija P Dasmahapatra; Edward A Sausville; Krishnendu K Roy Journal: Mol Cancer Ther Date: 2003-11 Impact factor: 6.261
Authors: J Verweij; A van Oosterom; J-Y Blay; I Judson; S Rodenhuis; W van der Graaf; J Radford; A Le Cesne; P C W Hogendoorn; E D di Paola; M Brown; O S Nielsen Journal: Eur J Cancer Date: 2003-09 Impact factor: 9.162
Authors: Christopher R Garrett; Domenico Coppola; Robert M Wenham; Christopher L Cubitt; Anthony M Neuger; Timothy J Frost; Richard M Lush; Daniel M Sullivan; Jin Q Cheng; Saïd M Sebti Journal: Invest New Drugs Date: 2010-07-20 Impact factor: 3.850
Authors: María Gabriela Cabrera-Serra; Jacob Lorenzo-Morales; Marialina Romero; Basilio Valladares; José E Piñero Journal: Parasitol Res Date: 2007-01-06 Impact factor: 2.289
Authors: Marion Le Grand; Kathleen Kimpton; Christine C Gana; Emanuele Valli; Jamie I Fletcher; Maria Kavallaris Journal: ACS Pharmacol Transl Sci Date: 2020-01-23
Authors: Andrean L Simons; Arlene D Parsons; Katherine A Foster; Kevin P Orcutt; Melissa A Fath; Douglas R Spitz Journal: J Oncol Date: 2009-09-02 Impact factor: 4.375